Abstract:Chimeric antigen receptor (CAR) T-cell therapy has achieved notable success in treating hematological cancers but faces significant challenges in solid-tumor treatment and overall efficacy. Key limitations include T-cell exhaustion, tumor relapse, immunosuppressive tumor microenvironments (TME), immunogenicity, and antigen heterogeneity. To address these issues, various genetic engineering strategies have been proposed. Approaches such as overexpression of transcription factors or metabolic armoring and dynamic CAR regulation are being explored to improve CAR T-cell function and safety. Other efforts to improve CAR T-cell efficacy in solid tumors include targeting novel antigens or developing alternative strategies to address antigen diversity. Despite the promising preclinical results of these solutions, challenges remain in translating CAR T-cell therapies to the clinic to enable economically viable access to these transformative medicines. The efficiency and scalability of autologous CAR T-cell therapy production are hindered by traditional, manual processes which are costly, time-consuming, and prone to variability and contamination. These high-cost, time-intensive processes have complex quality-control requirements. Recent advancements suggest that smaller, decentralized solutions such as microbioreactors and automated point-of-care systems could improve production efficiency, reduce costs, and shorten manufacturing timelines, especially when coupled with innovative manufacturing methods such as transposons and lipid nanoparticles. Future advancements may include harmonized consumables and AI-enabled technologies, which promise to streamline manufacturing, reduce costs, and enhance production quality.

Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment

Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game

Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Tuning the performance of CAR T cell immunotherapies

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

Challenges and future perspectives for high-throughput chimeric antigen receptor T cell discovery

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks